( December 30, 2025, 19:38 GMT | Official Statement) -- MLex Summary: US antitrust claims against Takeda Pharmaceutical and TWi Pharmaceuticals alleging an illegal reverse payment agreement to restrain competition for Dexilant and its generic equivalents should move forward, Walgreens, Kroger, Albertsons, and others told a California federal judge. "Plaintiffs did not have the TWi Settlement Agreement at the time that they drafted their complaints, but it unambiguously supports their allegation that Takeda agreed not to launch an AG in competition with TWi," they said in a sur-reply opposing dismissal of claims before the Northern District of California.See attached document....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.